NO931117L - Steroidderivater - Google Patents

Steroidderivater

Info

Publication number
NO931117L
NO931117L NO93931117A NO931117A NO931117L NO 931117 L NO931117 L NO 931117L NO 93931117 A NO93931117 A NO 93931117A NO 931117 A NO931117 A NO 931117A NO 931117 L NO931117 L NO 931117L
Authority
NO
Norway
Prior art keywords
halo
steroid derivatives
cholesterol
ce2ce3
dlng
Prior art date
Application number
NO93931117A
Other languages
English (en)
Norwegian (no)
Other versions
NO931117D0 (no
Inventor
Robert Allen Archer
Lisa Selsam Beavers
Robert Alan Gadski
Ho-Shen Lin
Don B Mcclure
Jefferson Ray Mccowan
Joseph Matthew Pawlak
Ashraff Ali Rampersaud
Robert John Schmidt
Teri Ann Schreyer
Melvin Joseph Yu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO931117D0 publication Critical patent/NO931117D0/no
Publication of NO931117L publication Critical patent/NO931117L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0029—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0011—Unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO93931117A 1992-03-27 1993-03-25 Steroidderivater NO931117L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85890892A 1992-03-27 1992-03-27
US1898593A 1993-03-03 1993-03-03

Publications (2)

Publication Number Publication Date
NO931117D0 NO931117D0 (no) 1993-03-25
NO931117L true NO931117L (no) 1993-09-28

Family

ID=26691704

Family Applications (1)

Application Number Title Priority Date Filing Date
NO93931117A NO931117L (no) 1992-03-27 1993-03-25 Steroidderivater

Country Status (12)

Country Link
EP (1) EP0562849A2 (enExample)
JP (1) JPH0656670A (enExample)
CN (1) CN1081682A (enExample)
AU (1) AU3551493A (enExample)
BR (1) BR9301342A (enExample)
CA (1) CA2092766A1 (enExample)
CZ (1) CZ50593A3 (enExample)
FI (1) FI931373A7 (enExample)
HU (1) HUT64082A (enExample)
IL (1) IL105050A0 (enExample)
MX (1) MX9301653A (enExample)
NO (1) NO931117L (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2724174B1 (fr) 1994-09-06 1997-01-17 Roussel Uclaf Procede de preparation d'un derive steroide 17beta-carboxy et nouveaux intermediaires
US6444659B1 (en) * 1996-11-28 2002-09-03 Cognis Deutschland Gmbh Use of mixtures of active substances, containing phytostenols and/or phytostenol esters and potentiators, for the production of hypocholesterolemic agents
CN1063449C (zh) * 1996-12-27 2001-03-21 中国科学院广州化学研究所 一种胆甾醇化合物及其提取方法
JP3873097B2 (ja) * 1997-11-06 2007-01-24 独立行政法人理化学研究所 抗肥満剤及び脂質代謝改善剤
US6531462B2 (en) 1997-11-06 2003-03-11 Riken Medicament for treating obesity and improving lipid metabolism
US6093389A (en) * 1997-12-01 2000-07-25 American Cyanamid Company Methods and compositions for attracting and controlling termites
GB9804861D0 (en) 1998-03-06 1998-04-29 Res Inst Medicine Chem Chemical compounds
US6579862B1 (en) 1999-01-12 2003-06-17 Council Of Scientific & Industrial Research Method of treating hyperlipidemic and hyperglycemic conditions in mammals using pregnadienols and pregnadienones
DK1392713T3 (da) * 2001-05-03 2008-02-18 Univ Chicago Lever-X-receptoragonister
US20070197484A1 (en) * 2001-05-03 2007-08-23 Ching Song Method of treating disorder related to high cholesterol concentration
US7078396B2 (en) 2001-05-03 2006-07-18 Arch Development Corporation Method of treating disorder related to high cholesterol concentration
EP1450816A4 (en) * 2001-11-08 2008-02-13 Univ Chicago METHOD OF TREATING DISORDERS RELATED TO HIGH CHOLESTEROL RATE
AU2002356919B2 (en) * 2001-11-08 2008-04-17 The University Of Chicago Method of treating disorder related to high cholesterol concentration
US20110190323A1 (en) 2008-08-28 2011-08-04 President And Fellows Of Harvard College Cortistatin analogues and syntheses thereof
US8829213B2 (en) 2009-07-29 2014-09-09 The University Of Chicago Liver X receptor agonists
WO2013134311A1 (en) * 2012-03-07 2013-09-12 Ligand Pharmaceuticals, Inc. Steroid hormone and cholesterol pathways as one unified homestatic system
AU2014369834B2 (en) 2013-12-24 2018-12-20 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
WO2016182932A1 (en) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Cortistatin analogues, syntheses, and uses thereof
EP3316889A4 (en) 2015-07-01 2018-11-14 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof
US9637514B1 (en) 2015-10-26 2017-05-02 MAX BioPharma, Inc. Oxysterols and hedgehog signaling
CN111973606B (zh) * 2019-05-22 2023-05-12 王伟 一种化合物治疗血管增生以及糖尿病视网膜病变的新用途
CN116514893B (zh) * 2022-01-28 2025-12-05 珂阑(上海)医药科技有限公司 甾类化合物、其制备方法和应用
WO2023205801A2 (en) 2022-04-22 2023-10-26 Asteroid Therapeutics Steroidal compositions and methods of treating lipogenic cancers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH372297A (de) * 1959-02-10 1963-10-15 Ciba Geigy Verfahren zur Herstellung von 4-2-tert.-Aminomethyl-3-keto-steroiden
US3256302A (en) * 1960-10-20 1966-06-14 Parke Davis & Co 2-hydroxymethylene-17alpha-ethinyl-17beta-hydroxy-19-nor-4-androsten-3-one
US3314977A (en) * 1962-06-18 1967-04-18 Searle & Co Optionally 17alpha-alkylated 3-oxygenated 2alpha-dialkylaminomethyl-5alpha-androstan-17beta-ols and esters thereof
GB1015214A (en) * 1963-03-11 1965-12-31 Merck Ag E Cholesterol derivatives and preparation thereof
US3980638A (en) * 1974-09-20 1976-09-14 The Upjohn Company Testosterone derivatives
ES472877A1 (es) * 1977-08-29 1979-02-16 Searle & Co Procedimiento para preparar derivados de 25-alquilcolesterol
US4297350A (en) * 1978-10-10 1981-10-27 The Upjohn Company Male contraceptive steroids and methods of use
JP2550777B2 (ja) * 1990-06-29 1996-11-06 日立化成工業株式会社 ステロイドケトン系化合物，その製造法，非線形光学材料および非線形光学素子

Also Published As

Publication number Publication date
BR9301342A (pt) 1993-10-05
FI931373L (fi) 1993-09-28
EP0562849A2 (en) 1993-09-29
MX9301653A (es) 1994-02-28
EP0562849A3 (enExample) 1994-02-16
FI931373A7 (fi) 1993-09-28
JPH0656670A (ja) 1994-03-01
CN1081682A (zh) 1994-02-09
HU9300901D0 (en) 1993-06-28
NO931117D0 (no) 1993-03-25
FI931373A0 (fi) 1993-03-26
CA2092766A1 (en) 1993-09-28
IL105050A0 (en) 1993-07-08
HUT64082A (en) 1993-11-29
AU3551493A (en) 1993-09-30
CZ50593A3 (en) 1993-12-15

Similar Documents

Publication Publication Date Title
NO931117L (no) Steroidderivater
Lewis et al. Warfarin stereochemical aspects of its metabolism and the interaction with phenylbutazone
BJERSING et al. Biosynthesis of steroids by granulosa cells of the porcine ovary in vitro
Einarsson et al. Bile acid synthesis in man: assay of hepatic microsomal cholesterol 7 alpha-hydroxylase activity by isotope dilution-mass spectrometry.
DK1090029T3 (da) 14,15-Cyclopropansteroider fra 19-norandrostan-rækken, fremgangsmåde til deres fremstilling, og farmaceutiske præparater indeholdende disse forbindelser
IE44865L (en) Steroid-containing composition
ATE241990T1 (de) 3-beta-hydroxylierte natürliche steroidderivate enthaltende arzneimittelzusammensetzungen und ihre verwendung
NO20013161L (no) Preparater av ileum-gallesyretransportinhibitorer og kolesterylesteroverföringsproteininhibitorer for kardiovaskul¶reindikasjoner
DE68920128D1 (de) Sulfonsäure-substituierte aromatische Steroide als 5-Alpha-Reduktase-Inhibitoren.
DE69628909D1 (de) Liposomformulierung von 5-beta steroiden
DK73594A (da) Fremgangsmåde til fremstilling af 17-substituerede 4-aza-5,7-androstadien-3-on-derivater
NO942165L (no) Glykosylerte steroidderivater for transport på tvers av biologiske membraner og fremgangsmåte for fremstilling av disse
NO20014657D0 (no) Preparater og fremgangsmåter for å påvirke nivåene av high density lipoprotein (HDL)-kolesterol og apolipoprotein A1, verylow density lipoprotein (VLDL)-kolesterol og low densitylipoprotein (LDL)-kolesterol
DK160993C (da) 17beta-methoxycarbonylderivater af androstan-raekken, fremgangsmaade til deres fremstilling, farmaceutisk praeparat indeholdende disse derivater samt anvendelse deraf til fremstilling af et middel til behandling af inflammation eller allergi
BR0307027A (pt) Compostos derivados de nitróxi de compostos esteróides, uso dos compostos, e, formulações farmacêuticas
NO20013632D0 (no) Steroide sulfataseinhibitorer og fremgangsmåter for å fremstille og anvende disse
Anderson et al. Regulation of steroidogenesis in rat Leydig cells in culture: effect of human chorionic gonadotropin and dibutyryl cyclic AMP on the synthesis of cholesterol side chain cleavage cytochrome P-450 and adrenodoxin
FI893908A0 (fi) Framstaellning av transdermala laekemedel som innehaoller steroliner och/eller spiroketaliner.
NO931905D0 (no) 8-en-19, 11beta-broede steroider, deres fremstilling og farmasoeytiske preparater inneholdende disse
Heinrichs et al. The selective stimulation, inhibition, and physicochemical alteration of the 7-and 16α-hydroxylases of 3β-hydroxyandrost-5-en-17-one and drug-metabolizing enzymes in hepatic microsomal fractions
Walsh This Month in Investigative Urology the Role of Estrogen/Androgen Synergism in the Pathogenesis of Benign Prostatic Hyperplasia
Rodney et al. The common mode of action of three new classes of inhibitors of cholesterol biosynthesis
Sybulski Testosterone metabolism by rat placenta
Kadohama et al. Inhibitory effects of some steroidal 6-methylene derivatives on 5α-reductase activity in human and rat prostate
Klaassen Studies on the mechanism of spironolactone protection against indomethacin toxicity